This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Adult 18 years of age or older
Able to give informed consent.
Able to comprehend and willing to follow instructions for study procedures as called for by the protocol
Capable of lying still and supine within the PET/CT scanner for up to 75 minutes.
None
Washington University School of Medicine
Lead sponsor
National Cancer Institute (NCI)
Collaborator